GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.72 USD | -0.21% |
|
+2.67% | -16.41% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +10.97% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% | ||
| 3.80% | 7 M€ | -.--% | - | |
| 3.55% | 1 M€ | +0.15% | - | |
| 2.90% | 562 M€ | +1.65% | ||
| 2.66% | 17 M€ | +7.73% | - | |
| 2.62% | 458 M€ | +4.08% | ||
| 2.58% | 6 M€ | +8.97% | - | |
| 2.27% | 2 M€ | +10.27% | ||
| 1.67% | 1 M€ | +2.21% | - | |
| 1.48% | 9 M€ | -4.31% | - | |
| 1.26% | 8 M€ | +5.66% | ||
| 1.26% | 13,519 M€ | +7.14% | ||
| 1.23% | 4,592 M€ | +11.18% | ||
| 1.21% | 253 M€ | +7.93% | ||
| 1.16% | 104 M€ | +10.57% | ||
| 1.04% | 800 M€ | +6.86% | ||
| 1.01% | 1,100 M€ | +4.32% | ||
| 1.00% | 5 M€ | -72.95% | - | |
| 0.98% | 3 M€ | 0.00% | - | |
| 0.96% | 2 M€ | +20.44% | - | |
| 0.95% | 9 M€ | -.--% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 84.36B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
